GELITA DO BRASIL LTDA

GELITA Launches Ultra-Low Endotoxin MEDELLAPRO Gelatin for Sensitive Biomedical Applications

- GELITA has launched MEDELLAPRO Ultra Low Endotoxin gelatin, featuring fewer than ten endotoxin units per gram, to support advanced biomedical product development. - The new excipient expands GELITA's Endotoxin Controlled Excipients portfolio, targeting applications such as surgical sealants, hemostatic agents, scaffolds, and drug delivery systems. - GELITA states these products could enable breakthroughs in drug delivery, vaccine stabilisation, tissue engineering, 3D bioprinting, and regenerative medicine. - The company will showcase MEDELLAPRO and VACCIPRO at BIO International 2026 in San Diego, alongside advancing animal-free recombinant collagen proteins.